Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress

- ALD2510 antibody shows promising tolerability and efficacy results for treatment of gynecologic and breast cancers
- Preclinical results to be presented during SITC congress on November 8-12, in Boston, MA

Paris, France, November 2, 2022 – Alderaan Biotechnology, a preclinical stage biotech company focused on monoclonal antibody development for the treatment of cancer, today announces it will present the most recent development of its new antibody candidate ALD2510 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting on November 8-12, 2022, in Boston (MA, USA). The poster will cover its promising preclinical results on tolerability and manufacturability, as well as the potential of the antibody for the treatment of gynecologic and breast cancers.

Entitled 'ALD2510: Next Generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers,' the poster presents the identification of the new antibody candidate, highlighting the study results in terms of tumour growth inhibition in animal models in gynecologic and breast cancers, the tolerability of the antibody in cynomolgus monkeys and its manufacturability.

Regulatory T cells (Treg) inhibit immune responses in many solid cancers and high infiltration by Treg cells has been associated with poor survival in various types of cancer. Alderaan Biotechnology has been developing ALD2150, a low-fucose IL-2-sparing anti-CD25 antibody designed for the selective depletion of Treg; boosting the immune effector functions within the tumor microenvironment. This makes it a promising candidate for the treatment of solid tumors, especially in gynecologic and breast cancers, where there are still significant unmet medical needs.

“We are thrilled to share our latest developments with the immunotherapy community at the SITC congress,” said Arnaud Foussat, CEO of Alderaan Biotechnology. “We are at a key stage in our preclinical development, where our lead candidate, ALD2150, has shown results indicating excellent tolerability and manufacturability. We believe modulating regulatory T cells can bring strong clinical benefits to cancer patients where chemotherapy or prior immunotherapy approaches have failed.”

This presentation is an important step in Alderaan Biotechnology’s clinical development, as it has successfully identified its future clinical candidate, ALD2150, which has passed the requirements for manufacturability, potency and preliminary safety. The company demonstrated the strong activity of anti-CD25 specific, IL-2-sparing monoclonal antibodies as monotherapy in models of gynecologic cancers leading to a cure in most animals and to the development of a memory immune response against the tumors. Alderaan Biotechnology plans to enter clinical phase in 2024.
About Alderaan Biotechnology

Alderaan Biotechnology is a preclinical stage biotech company developing novel therapies to treat cancer by targeting cells from the immune system. The company focuses on the development of monoclonal antibodies for the treatment of cancer with technologies aiming at Treg depletion in solid tumours. Founded in 2017 and headquartered in Paris, France, Alderaan Biotechnology works with world-class teams in the field of immunomodulation and immunotherapy of cancer. The company raised €1.5M ($1.7M) in 2017 from co-founder AdBio partners and €18.5M ($20.7M) in 2019 from AdBio partners and Medicxi. Alderaan Biotechnology works in partnership with the French national Institute for health and medical research (INSERM) and with the Institut Paoli Calmettes, Marseille, France.

www.alderaan-biotechnology.com

Press and Analyst Contacts

Andrew Lloyd and Associates
Céline Gonzalez / Saffiyah Khalique
celine@ala.com / saffiyah@ala.com
UK: +44 1273 952 481
US: + 1 617 202 4491